Stevanato Group Alina pen injector wins EU marketing authorizations for liraglutide products
STVN•EU marketing authorizations for Alina-based liraglutide products
Liraglutide combination products using Stevanato Group’s Alina pen injector won marketing authorizations in multiple European countries.
Clearance covers diabetes and weight-management therapies, supporting broader commercial rollout of the Alina platform across Europe.
Approved configurations include Alina 30 for diabetes indications, Alina 50 for weight management.
